Filing Details

Accession Number:
0001209191-21-021943
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-18 20:44:39
Reporting Period:
2021-03-16
Accepted Time:
2021-03-18 20:44:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1404644 Neoleukin Therapeutics Inc. NLTX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1806254 Robert Ho C/O Neoleukin Therapeutics, Inc.
188 East Blaine Street, #450
Seattle WA 98102
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-16 25,000 $0.00 28,000 No 4 M Direct
Common Stock Disposition 2021-03-17 6,497 $11.01 21,503 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2021-03-16 25,000 $0.00 25,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,000 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
  3. The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  4. The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.